VIA
IMVT icon

Virtus Investment Advisers’s Immunovant IMVT Stock Holding History

Virtus Investment Advisers’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$375K Sell
9,732
-588
-6% -$17.9K 0.09% 316
2026
Q1 		$256K Buy
10,320
+251
+2% +$6.5K 0.07% 310
2025
Q4 		$256K Buy
10,069
+2,931
+41% +$65.4K 0.07% 316
2025
Q3 		$115K Buy
7,138
+1,239
+21% +$20.1K 0.03% 410
2025
Q2 		$94.4K Sell
5,899
-54
-0.9% -$817 0.03% 355
2025
Q1 		$102K Buy
+5,953
New +$125K 0.03% 416

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Virtus Investment Advisers's IMVT Position: Q2 2026 in Review

Virtus Investment Advisers reduced its Immunovant (IMVT) stake by 5.7% in Q2 2026, selling an estimated $17.9K and leaving 9,732 shares worth $375K. The position accounts for 0.09% of the portfolio, ranked #316.

Virtus Investment Advisers first reported a position in IMVT in Q1 2025 and has held it in 6 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Virtus Investment Advisers held 9,732 shares of Immunovant worth $375K as of Q2 2026.
  • Virtus Investment Advisers sold 588 Immunovant shares in Q2 2026, an estimated $17.9K.
  • Immunovant made up 0.09% of Virtus Investment Advisers's portfolio in Q2 2026, its #316 holding.
  • Virtus Investment Advisers first reported a position in Immunovant in Q1 2025 and has held it in 6 quarters since.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.